The Role of Serum Chitinase-3-Like 1 Protein (YKL-40) Level and its Correlation with Proinflammatory Cytokine in Patients with Rheumatoid Arthritis
Main Article Content
Abstract
Chitinase-3-like 1 protein (YKL-40) is a glycoprotein primarily produced in the arthritic joint and plays a crucial role in inflammatory processes. The aim of the study is to establish the role of YKL-40 as a biomarker for rheumatoid arthritis (RA) compared to proinflammatory biomarkers and disease activity. The study included 58 patients and 18 control. Diseases activity score (DAS-28) and clinical disease activity index (CDAI) were measured. Serum level of YKL-40, tumor necrosis factor-α (TNF-α), interleukin-1B (IL-1β), erythrocyte sedimentation (ESR), rheumatoid factor (RF), C-reactive protein (CRP), and anti-citrullinated protein antibody (ACPA) were assessed. The results showed that the median serum YKL-40 level which was 5.42 ng/ml, the TNF-a level which was 123.6 ng/ml, and the IL-1B level which was 204.365 pg/dl were significantly higher in patients compared to control 3.28 (1.58–4.99) ng/ml, 56.47 (9.38–77.01) ng/ml and 67.887 (15.493–122.689)pg/dl respectively. There was no correlation between serum YKL-40 and disease activity, while there were significant associations observed with TNF-α (r=0.5,p =0.0001) and IL-1β (r=0.41, p=0.001). YKL-40 indicating good levels of RA prediction at 2.47 ng/ml, sensitivity 87.9%, specificity 58.6%, accuracy 78.1%, PPV 80.9%, and NPV 70.8%. In conclusion, a higher level of serum YKL-40 is found in RA patients. The findings from our study suggest a strong association between YKL-40 and the proinflammatory biomarkers. As a result, these biomarkers together might play a role in RA pathogenesis, and YKL-40 may be used as a potential diagnostic biomarker for RA.
Received 6/5/2021
Accepted 6/7/2021
Published Online First 20/3/2022
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.
Giannini D, Antonucci M, Petrelli F, Bilia S, Alunno A, Puxeddu I. One year in review 2020: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2020;38:387–97.
Oderda GM, Lawless GD, Wright GC, Nussbaum SR, Elder R, Kim K, et al. The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. Per Med [Internet]. 2018 Jul;15(4):291–301. Available from: https://www.futuremedicine.com/doi/10.2217/pme-2018-0001
Brooks PM. The burden of musculoskeletal disease—a global perspective. Clin Rheumatol. 2006;25(6):778–81.
Gossec L, Combescure C, Rincheval N, Saraux A, Combe B, Dougados M. Relative clinical influence of clinical, laboratory, and radiological investigations in early arthritis on the diagnosis of rheumatoid arthritis. Data from the French Early Arthritis Cohort ESPOIR. J Rheumatol. 2010;37(12):2486–92.
Mouterde G, Rincheval N, Lukas C, Daien C, Saraux A, Dieudé P, et al. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. Arthritis Res Ther. 2019;21(1):140.
Wu C-Y, Yang H-Y, Luo S-F, Lai J-H. From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis. Int J Mol Sci. 2021;22(2):686.
Reed E, Hedström AK, Hansson M, Mathsson-Alm L, Brynedal B, Saevarsdottir S, et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther. 2020;22(1):1–11.
Rocha S de B, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol. 2019;59:2.
Narayan V, Pallinti V, Ganesan N. A study of serum YKL-40 and its correlation with traditional biomarkers in rheumatoid arthritis patients. Indian J Rheumatol. 2019;14(3):200.
Lee YH, Song GG. YKL-40 Levels in Rheumatoid Arthritis and Their Correlation with Disease Activity: A Meta-analysis. J Rheum Dis. 2019;26(4):257–63.
He CH, Lee CG, Cruz CS Dela, Lee C-M, Zhou Y, Ahangari F, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4(4):830–41.
Mateen S, Moin S, Shahzad S, Khan AQ. Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species. PLoS One. 2017;12(6):e0178879.
Brzustewicz E, Bryl E. The role of cytokines in the pathogenesis of rheumatoid arthritis – Practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine [Internet]. 2015 Dec;76(2):527–36. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1043466615300491
Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23):6008.
Shehu S, Kurya AU, Aliyu U, Sharma DC. Role of Inflammatory Cytokines in the Pathogenesis of Rheumatoid Arthritis and Novel Therapeutic Targets. Asian J Immunol. 2020;37–46.
Li XZ, Zhao SC, Cai XL, Wang YF, Chen J, Ma XF, et al. Differences in expression of YKL-40 and TLR4 in nasal sinus mucosa of chronic sinusitis patients with and without nasal polyps. J Biol Regul Homeost Agents. 2018;32(3):537–43.
Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis. 2010;69(9):1589–95.
Hoo ZH, Candlish J, Teare D. What is an ROC curve? Emerg Med J. 2017;34(6).
Kazakova MH, Batalov AZ, Mateva NG, Kolarov ZG, Sarafian VS. YKL-40 and cytokines-A new diagnostic constellation in rheumatoid arthritis? Folia Med (Plovdiv). 2017;59(1):37–42.
Jafari-Nakhjavani MR, Ghorbanihaghjo A, Bagherzadeh-Nobari B, Malek-Mahdavi A, Rashtchizadeh N. Serum YKL-40 levels and disease characteristics in patients with rheumatoid arthritis. Caspian J Intern Med. 2019;10(1):92.
Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8(4):e60635.
S. Johansen Paul A. Price, Mohammed Sharif, Julia JRK. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol. 2001;30(5):297–304.
Arleevskaya MI, Gabdoulkhakova AG, Filina J V, Zabotin AI, Tsibulkin AP. Mononuclear phagocytes in rheumatoid arthritis patients and their relatives–family similarity. Open Rheumatol J. 2011;5:36.
Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang M-J, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479–501.
Curtis JR, Weinblatt ME, Shadick NA, Brahe CH, Østergaard M, Hetland ML, et al. Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. Arthritis Res Ther. 2021;23(1):1–13.
Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol. 2001;19(6):655–60.
Kassem E, Mahmoud L, Salah W. Study of Resistin and YKL-40 in rheumatoid arthritis. J Am Sci. 2010;6(10):1004–12.
Al-Sayed MT, Mohammed AS, Mohammed AHAF, Ibrahim AM, Moshrif A. Diagnostic and prognostic values of serum HSP70 and YKL-40 in patients with rheumatoid arthritis. Int J Clin Rheumtol. 2017;12(3):59.
Kazakova M, Batalov A, Deneva T, Mateva N, Kolarov Z, Sarafian V. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int. 2013;33(2):341–6.
Shen R, Ren X, Jing R, Shen X, Chen J, Ju S, et al. Rheumatoid factor, anti-cyclic citrullinated peptide antibody, C-reactive protein, and erythrocyte sedimentation rate for the clinical diagnosis of rheumatoid arthritis. Lab Med. 2015;46(3):226–9.
Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J. 2004;380(3):651–9.
Mohammadi E, Vatanpour H, Shirazi FH. Immunomodulatory effects of bee venom in human synovial fibroblast cell line. Iran J Pharm Res IJPR. 2015;14(1):313.